Clonal hematopoiesis in patients with dyskeratosis congenita. Issue 12 (21st October 2016)

• Record Type: Journal Article
• Authors: Perdigones, Nieves; Perin, Juan C.; Schiano, Irene; Nicholas, Peter; Biegel, Jaclyn A.; Mason, Philip J.; Babushok, Daria V.; Bessler, Monica
• Is Part Of: American journal of hematology. Volume 91:Issue 12(2016:Dec.)
• Page Start: 1227
• Page End: 1233
• Publication Date: 2016-10-21
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.24552
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract : Dyskeratosis congenita (DC) is a rare inherited telomeropathy most frequently caused by mutations in a number of genes all thought to be involved in telomere maintenance. The main causes of mortality in DC are bone marrow failure as well as malignancies including leukemias and solid tumors. The clinical picture including the degree of bone marrow failure is highly variable and factors that contribute to this variability are poorly understood. Based on the recent finding of frequent clonal hematopoiesis in related bone marrow failure syndromes, we hypothesized that somatic mutations may also occur in DC and may contribute at least in part to the variability in blood production. To evaluate for the presence of clonal hematopoiesis in DC, we used a combination of X‐inactivation, comparative whole exome sequencing (WES) and single nucleotide polymorphism array (SNP‐A) analyses. We found that clonal hematopoiesis in DC is common, as suggested by skewed X‐inactivation in 8 out of 9 female patients compared to 3 out of 10 controls, and by the finding of acquired copy neutral loss‐of‐heterozygosity on SNP‐A analysis. In addition, 3 out of 6 independent DC patients were found to have acquired somatic changes in their bone marrow by WES, including a somatic reversion in DKC1, as well as missense mutations in other protein coding genes. Our results indicate that clonal hematopoiesis is a common feature of DC, and suggest that such somatic changes, though commonly expected to indicate malignancy, may lead to improved blood cell production or stem cell survival. Am. J. Hematol. 91:1227–1233, 2016. © 2016 Wiley Periodicals, Inc.